Predicting progression-free survival in hormone-receptor positive (HR+/HER2–) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach

Key Points

• Progression-free survival can be accurately predicted using machine learning techniques, enhancing treatment planning.
• Machine learning models, using clinical data, show strong performance in predicting outcomes for patients receiving CDK4/6 inhibitors.
• Observational analysis of hormone-receptor positive metastatic breast cancer demonstrates the model’s utility in clinical settings.
• This approach highlights the potential for machine learning to revolutionize personalized treatment in cancer care.